Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Why Cancer-Fighting Stocks & ETFs Are Soaring

By Zacks Investment ResearchStock MarketsJun 03, 2019 02:46AM ET
Why Cancer-Fighting Stocks & ETFs Are Soaring
By Zacks Investment Research   |  Jun 03, 2019 02:46AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

In this episode of ETF Spotlight, I speak with Brad Loncar, CEO of Loncar Investments. Brad is in Chicago to attend the annual meeting of ASCO (American Society of Clinical Oncology). It is the world’s largest and most prestigious cancer conference where participants learn about the latest developments in treating the disease.

Brad explains why ASCO is so important and how he uses it as an investor.

The global market for cancer drugs is estimated to be about $123 billion and big players are investing heavily to gain an edge in this increasingly competitive market. Pharmaceutical giant Bristol-Myers (NYSE:BMY) , a pioneer in immunotherapy, is acquiring rival Celgene (NASDAQ:CELG) for $74 billion.

Merck (NYSE:MRK) is acquiring cancer drug developer Peloton Therapeutics for $1.05 billion. The announcement came as Peloton was preparing for its IPO. Earlier this year, Eli Lilly (NYSE:LLY) bought Loxo Oncology for $8 billion.

Should we expect more M&A in the space?

Brad created the index for the Loncar Cancer Immunotherapy ETF CNCR, which invests in companies at the forefront of immunotherapy research. He explains why immunotherapy, which harnesses the body’s immune system to fight cancer, is often called a game changer for cancer treatment.

He also talks about important developments in the space and promising work being done by some smaller, innovative biotech companies.

Mirati Therapeutics (NASDAQ:MRTX) , Iovance Biotherapeutics (formerly Lion Biotechnologies) (NASDAQ:IOVA) and Nektar Therapeutics (NASDAQ:NKTR) are soaring today. These are among the top holdings in CNCR. Find out more about them on the podcast.

WSJ recently reported that AstraZeneca (NYSE:AZN) is planning to target early stages of the disease, whereas traditionally, pharma companies focus on drugs that treat advanced forms of cancer. Will the new approach help AstraZeneca gain an edge over competitors?

Health Care is the worst performing sector this year, thanks mainly to policy concerns. Will there be a big focus on policy related issues at the conference?

Tune into the podcast to learn more.

Brad also created the index for the Loncar China BioPharma ETF (SI:CHNA) which focuses on the booming biopharma industry in China. To learn more about these ETFs, please visit

Please also visit the Cancer Research Institute to learn about this cancer treatment and clinical trials.

Make sure to be on the lookout for the next edition of ETF Spotlight! If you have any comments or questions, please email

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>

Eli Lilly and Company (LLY): Free Stock Analysis Report

AstraZeneca PLC (AZN): Free Stock Analysis Report

Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

Merck & Co., Inc. (MRK): Free Stock Analysis Report

Loncar Cancer Immunotherapy ETF (CNCR): ETF Research Reports

Celgene Corporation (CELG): Free Stock Analysis Report

Mirati Therapeutics, Inc. (MRTX): Free Stock Analysis Report

Nektar Therapeutics (NKTR): Free Stock Analysis Report

Lion Biotechnologies, Inc. (IOVA): Free Stock Analysis Report

Loncar China BioPharma ETF (CHNA): ETF Research Reports

Original post

Zacks Investment Research
Why Cancer-Fighting Stocks & ETFs Are Soaring

Related Articles

Why Cancer-Fighting Stocks & ETFs Are Soaring

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email